Ivermectin's patent status is complex, with patents expiring and some applications facing challenges. Initially patented in the 1970s by Merck, the compound itself and its primary uses are now off-patent [1]. However, new formulations, delivery methods, or specific medical uses for ivermectin could still be eligible for patent protection.
When did the original ivermectin patents expire?
The foundational patents for ivermectin, developed by Merck, expired decades ago. This means that generic versions of the drug for its established antiparasitic uses are widely available.
Are there still patents related to ivermectin?
While the original patents have expired, companies may hold patents on novel formulations, combinations with other drugs, or new therapeutic applications of ivermectin. These subsequent patents can affect the market exclusivity for these specific innovations. DrugPatentWatch.com tracks such patent information [2].
Why are companies challenging ivermectin patents?
Companies may challenge existing patents on ivermectin if they believe these patents are invalid or if they intend to bring a generic version of a patented formulation or application to market. Such challenges are common in the pharmaceutical industry as patents approach expiration or when generic manufacturers seek to enter the market.
Can ivermectin be used for new medical conditions?
Research into ivermectin's potential efficacy for various medical conditions, including some viral infections, has been ongoing. If new, substantiated therapeutic uses are discovered and meet regulatory standards, these could potentially lead to new patent applications for those specific indications [2]. However, such applications would need to demonstrate novelty and inventiveness beyond existing patents.